Markets
Federal Reserve To Make Highly Anticipated Interest Rate Announcement This Week
The Eccles building, under construction (Kevin Dietsch/Getty Images)

December rate cut odds creep lower with Federal Reserve hawks out in full force

A cacophony of hawkish commentary.

Luke Kawa

The Federal Reserve’s more hawkish officials are out in force today making the case against any further easing in monetary policy, and in some cases, voicing disagreement with the cut delivered this week.

At the end of Fed Chair Jerome Powell’s press conference on Wednesday, during which he said a December reduction was “far from” a foregone conclusion, event contracts traded on Robinhood indicated about a 30% chance of no interest rate cut in December. That’s edged up to 33% after today’s commentary.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. Event contracts trading is offered by Robinhood Derivatives, LLC, a registered futures commission merchant with the CFTC.)

Here’s a smattering of Bloomberg headlines on today’s Fedspeak.

From Kansas City Fed President Jeffrey Schmid, who put out a release explaining his dissent at the last meeting in favor of no cut:

*FEDS SCHMID: JOB MARKET LARGELY IN BALANCE, INFLATION TOO HIGH

*SCHMID: MONETARY POLICY SHOULD LEAN AGAINST DEMAND GROWTH

From Dallas Fed President Lorie Logan (a nonvoting member of the Fed), speaking today at a conference:

*FEDS LOGAN: WOULDVE PREFERRED TO HOLD RATES STEADY THIS WEEK

*LOGAN: FED ALREADY MITIGATED EMPLOYMENT RISK WITH SEPTEMBER CUT

*LOGAN: I WOULD FIND IT DIFFICULT TO CUT RATES AGAIN IN DECEMBER

Atlanta Fed President Raphael Bostic (also a nonvoting member of the Fed), speaking on a panel at that same conference:

*BOSTIC: EVENTUALLY GOT BEHIND THIS WEEKS RATE CUT

*BOSTIC: PREFERABLE TO MOVE SLOWER WHEN SO LITTLE CLARITY

*BOSTIC: GLAD POWELL SAID DEC. CUT IS FAR FROM FOREGONE MOVE

Cleveland Fed President Beth Hammack (another nonvoting member), in comments during that panel with Bostic:

*HAMMACK: I WOULDVE PREFERRED TO HOLD RATES STEADY THIS WEEK

*HAMMACK: I THINK WERE RIGHT AROUND MY ESTIMATE OF NEUTRAL

*HAMMACK: FEDS POLICY IS BARELY RESTRICTIVE, IF AT ALL

*HAMMACK: INFLATION BROADER THAN TARIFFS; CORE SERVICES STRONG

What explains the relatively limited shift in prediction markets amid this cacophony of hawkish commentary?

First, some Federal Reserve officials are more important than others. At the current time, Chair Powell and Governor Waller are by far the most influential, with New York Fed President John Williams a fair bit behind the duo. These remarks are coming from less prominent Fed officials.

Secondly, we know that in the September dot plot, nine Federal Reserve officials thought the policy rate should end the year at its current level (3.875%) or higher, and 10 officials thought it should be lower — contingent on the economic outlook evolving broadly as they had anticipated at the time.

Unless these aforementioned comments come from members that have experienced a meaningful shift in views on how the economy has progressed from mid-September through this week, that means we’ve effectively identified four of the more hawkish members of the Federal Reserve. Three of these individuals will not be voting at the December meeting.

If the above is true, doing some light math, that would mean, at most, there are a maximum of six Fed officials out of 12 voting members who are predisposed to not cut interest rates in December based on the September dot plot.

To unpack: 19 Fed officials, 12 of which have a vote, with at least three of the other seven who seem to oppose further cuts (based on today’s remarks), and nine who thought back in September that rates should be no lower than they are now.

Of course, minds may have changed during the inter-meeting period already, and may change even more before the December decision. But right now it would be a fair guess that based on the September dot plot and the revealed preferences provided today, it’s still more likely that Fed officials have a modest tilt toward delivering a December rate cut.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.